Replies to post #2217 on Enanta Pharmaceuticals Inc (ENTA)

[vinmantoo]

Thanks Dew.

We remain committed to developing a combination regimen as a functional cure for chronic HBV patients. EDP-514, our core HBV core inhibitor with Fast Track designation, has demonstrated safe and potent antiviral activity in two phase 1 studies in different chronic HBV patient populations. Those who have high viral load, whom we refer to as viremic patients, and those who are on a treatment with a nucleoside reverse transcriptase inhibitor, whom we refer to as nuc-suppressed patients. These data suggest EDP-514 has the potential to be a best-in-class core inhibitor for HBV.

We remain focused on evaluating internal and external opportunities for additional components with alternative mechanisms to develop in combination with EDP-514 as we believe that a core inhibitor such as EDP-514 will ultimately be an important component of a successful combination regimen.

While the CC looks generally good, I was hoping for perhaps an update on the other drug(s) ENTA hopes can be combined with EDP-514. Even something as simple as we have several in-house candidate being investigated for possible combination therapy.

Still, nice to hear that the phase I safety trial data for ENTA's Covid protease inhibitor EDP-235 should be available this quarter.